Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.
1. A method for the treatment of actinic keratosis, comprising topically administering to a subject in need thereof, an effective amount of 2,5-dihydroxybenzenesulfonic acid (Dobesilate) or a pharmaceutically acceptable salt.
2. The method of claim 1 , wherein the salt is selected from the group consisting of: calcium 2,5-dihydroxybenzenesulfonate (calcium Dobesilate); potassium 2,5-dihydroxybenzenesulfonate (potassium Dobesilate); magnesium 2,5-dihydroxybenzenesulfonate (magnesium Dobesilate); diethylamine 2,5-dihydroxybenzenesulfonate (Ethamsylate).
3. The method of claim 2 , wherein the salt is calcium 2,5-dihydroxybenzenesulfonate (calcium Dobesilate).
4. The method of claim 2 , wherein the salt is potassium 2,5-dihydroxybenzenesulfonate (potassium Dobesilate).
5. The method of claim 1 , wherein the actinic keratosis is selected from the group consisting of: hypertrophic, atrophic, bowenoid, and acantholythic keratosis.
6. The method of claim 1 , wherein the compound is administered at least once per week.
7. The method of claim 6 , wherein the compound is administered at least once per day.
8. The method of claim 7 , wherein the compound is administered at least twice per day.
9. The method of claim 1 , wherein the compound is present in a pharmaceutical composition in an amount of at least about 1% w/w.
10. The method of claim 9 , wherein the compound is present in a pharmaceutical composition in an amount of at least about 2.5% w/w.
11. The method of claim 10 , wherein the compound is present in a pharmaceutical composition in an amount of at least about 5% w/w.
12. The method of claim 11 , wherein the compound is present in a pharmaceutical composition in an amount of at least about 10% w/w.
13. The method of claim 12 , wherein the compound is present in a pharmaceutical composition in an amount of at least about 15% w/w.
14. The method of claim 1 , wherein the compound is administered over a period of at least about one week.
15. The method of claim 14 , wherein the compound is administered over a period of at least about four weeks.
16. The method of claim 4 , wherein the potassium 2,5-dihydroxybenzenesulfonate (potassium Dobesilate) is administered as a cream at a concentration of at least about 2.5% w/w.
17. The method of claim 16 , wherein the potassium 2,5-dihydroxybenzenesulfonate (potassium Dobesilate) is administered as a cream at a concentration of at least about 5% w/w.
18. The method of claim 17 , wherein the cream further comprises one or more emollients and one or more emulsifiers.
19. The method of claim 16 , wherein the potassium 2,5-dihydroxybenzenesulfonate (potassium Dobesilate) is administered at least twice per day over a period of at least four weeks.
20. A method for the treatment of actinic keratosis, comprising topically administering to a subject in need thereof a cream comprising 5% of potassium 2,5-dihydroxybenzenesulfonic acid (potassium Dobesilate) w/w, wherein the cream is administered at least twice per day over a period of at least four weeks.